Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Corcept Therapeutics Incorporated made materially false and/or misleading statements and/or failed to disclose that: August 2020, Teva Pharmaceutical Industries Limited ("Teva") received approval from the U.S. Food and Drug Administration to market an off-patent version of Korlym, a best-selling Corcept product. Then on February 20, 2025, Seeking Alpha reported that a group of health insurers had filed a lawsuit against Corcept in California, accusing Corcept of manipulating the patent process in its efforts to "vigorously enforce" its intellectual property rights linked to Korlym, in an effort to stifle Teva's generic product launch. Following this news, Corcept's stock price fell over 11% on the same day.
In order to be eligible to join the CORT class action lawsuit, you must have incurred a loss on shares of Corcept Therapeutics Incorporated purchased during the class period listed above.
TOP
